Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most commonly reported bad side effects of Mounjaro are gastrointestinal: nausea, vomiting, diarrhoea, constipation and indigestion account for the majority of complaints, particularly in the first weeks of treatment or after a dose step. Most settle. A small number of side effects require prompt medical attention, and knowing which is which makes all the difference. Mounjaro (tirzepatide) is a prescription-only medicine; a clinical assessment by a prescriber considers your full medical picture before treatment begins, including which side effects to watch for specifically in your case.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most persistent misconception our prescribers encounter is this: if you feel rough in the first fortnight, something has gone wrong. It usually hasn't. Mounjaro slows gastric emptying and activates gut hormone receptors involved in appetite regulation, and your digestive system needs time to adjust. Nausea is the body's predictable response to that shift, not a sign the medicine is failing or causing damage. The NHS tirzepatide page lists nausea, vomiting, diarrhoea, constipation, indigestion, burping and fatigue as the most common effects, common in the clinical sense, meaning reported by a meaningful proportion of trial participants, not meaning they are severe or permanent.
The graduated dose schedule exists for exactly this reason. Starting at 2.5mg gives the body several weeks to adjust before the prescriber considers moving upward. That first pen's job is tolerance, not transformation. Side effects that arrive at 2.5mg almost always ease before the next step. If they don't, your prescriber needs to know, and a change in pace or approach is possible. The full side-effect profile for Mounjaro covers this in more detail, including which effects are most tied to specific doses.
The myth does real harm because it cuts both ways: some people push through effects they should report, and others stop treatment over normal adjustment symptoms. Neither outcome serves them well.
Acute pancreatitis is the one to know. In January 2026 the MHRA issued a Drug Safety Update specifically for GLP-1 receptor agonist medicines, confirming pancreatitis as an infrequent but potentially serious risk. The signal to act on is severe, persistent abdominal pain, the kind that doesn't pass, may radiate through to your back, and can come with vomiting. Stop treatment and seek urgent medical attention if that pattern appears. Do not wait to see if it settles overnight.
Gallbladder problems are also on the watch list. Rapid weight loss of any cause can raise the risk of gallstones, and symptoms (upper-right abdominal pain, nausea, sometimes fever) should be assessed by a clinician. Dehydration is a practical risk if vomiting or diarrhoea becomes severe enough that you cannot keep fluids down; that can affect kidney function and warrants medical review. Persistent diarrhoea on Mounjaro has its own practical guidance worth reading if that's your concern.
Allergic reactions are rare but real: significant swelling of the face, throat, lips or tongue, difficulty breathing, or a severe rash after injection are emergency signs. Injection-site reactions (redness, swelling, itching at the spot itself) are common and generally minor, but report anything that spreads or worsens. If your mood changes significantly, or you experience thoughts of self-harm, contact a clinician without delay.
Clinically serious effects are rare. What most people find genuinely bad about Mounjaro, practically speaking, is the disruption to ordinary life: planning meals around nausea, adjusting to unpredictable digestion, managing the sulphurous burping that some people experience, particularly after dose increases. These are not dangerous, but they are real and worth taking seriously rather than dismissing.
Timing matters here in a very practical way. People who start a new pen just before a long weekend (or who increase their dose when they have a big week ahead) sometimes find the first few days harder than expected because their routine is disrupted. Having plain, low-fat food available and keeping well hydrated gives the GI system less to work against. The burping side effect in particular surprises people; it's not listed prominently on packaging but it does appear in the clinical data and in the experience of many patients. Related breath changes are also worth reading about if that's something you've noticed.
Fatigue and headache often accompany the GI effects in the early weeks, partly because eating less changes energy availability. They tend to resolve as the body settles. None of this is to minimise the experience (a fortnight of nausea is miserable) but it is, for most people, temporary.
Every patient on a prescription medicine in the UK has the right to report a suspected side effect, however minor. The MHRA's Yellow Card scheme accepts reports from patients and carers directly, you do not need to go through a doctor first. These reports genuinely shape how the regulator monitors medicines after launch, which is particularly relevant for Mounjaro given its Black Triangle (▼) status indicating that additional MHRA surveillance is ongoing.
If you are a patient with us and a side effect is troubling you, our aftercare team is available seven days a week. You don't have to wait for your next scheduled review. The five most frequently reported Mounjaro side effects has practical tips for managing each one, and our broader side-effect page covers the full licensed spectrum. If you have questions before starting, our clinical team discusses all of this as part of the consultation, suitability, your specific risk profile, and what to watch for. That conversation happens before any prescription is written, not after.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.